Elena A. Dmitrieva

Elena A. Dmitrieva

Auto-generated profile, based on publicly available information

Elena A. Dmitrieva

Botkin Hospital Moscow Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 February 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ОKОlga L. Kochneva
Оlga L. Kochneva
Maria KislovaMaria Kislova
Maria Kislova
EZEvgenya I. Zhelnova
Evgenya I. Zhelnova
APAndrei A. Petrenko
Andrei A. Petrenko
EBElena A. Baryakh
Elena A. Baryakh
ENEugene Nikitin
Eugene Nikitin
We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels are significantly lower. Patients with CLL are more likely to have a severe course of COVID-19, with IL-6 levels acting as a consistent biomarker of disease severity. Ten patients had recurrent episodes, fatality rate of 20%. Overall survival did not differ between patients receiving ibrutinib monotherapy and anti-CD20 antibodies ± chemotherapy. It seems that the immunodeficiency inherent to CLL influences outcomes to a larger degree than does the treatment. Glucocorticoids are not associated with significant OS improvement whereas anti-cytokine compounds usage seemed to be beneficial in patients with mild pulmonary involvement. Our data attest to the necessity of reorganizing health care for patients with CLL. Early administration of effective antiviral compounds and tailored vaccination protocols are warranted.

7 June 2021 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
EPEvgeniy Vladimirovich Pochtar
Evgeniy Vladimirovich Pochtar
SLS. A. Lugovskaya
S. A. Lugovskaya
ENE. V. Naumova
E. V. Naumova
EDE. A. Dmitrieva
E. A. Dmitrieva
AKAlexander Kostin
Alexander Kostin
VDV. V. Dolgov
V. V. Dolgov
Profound immunological dysfunction is the key factor determining the development of infectious complications in chronic lymphocytic leukemia (CLL). The aim of this work is to assess the features of the subpopulation composition of T-lymphocytes (T-helpers (Th), cytotoxic T-lymphocytes (Tcyt), T regulatory cells (Treg), T-NK cells, naive Th, Th-memory, activated T-lymphocytes, TCRγδ cells) and NK cells in peripheral blood of patients with newly diagnosed chronic lymphocytic leukemia (CLL) and receiving ibrutinib therapy. Hematological and immunophenotypic studies have been performed in 30 patients with previously untreated CLL, 122 patients on ibrutinib therapy and 20 healthy donors. The subpopulation composition of T-lymphocytes (Th, Tcyt, Treg, T-NK, naive T-helpers, memory T-helpers, TCRγδ cells, activated T-lymphocytes) and NK cells has been assessed on flow cytometer (FACSCanto II (BD)) using the following panel of monoclonal antibodies: CD45, CD19, CD3, CD4, CD5, CD8, TCRγδ, CD127, CD16, CD56, CD57 CD45RA, CD45R0, HLA-DR, CD25. Compared to controls all CLL samples were found to have higher the absolute number of T-lymphocytes, NK cells and their subpopulations, T-helpers (especially of memory T-cells), cytotoxic T-cells, regulatory T-cells, TCRγδ T-cells, activated T-lymphocytes, increased cytotoxic potential of NK cells in previously untreated CLL patients. Patients who received ibrutinib therapy have registered a positive trend towards recovery of the subpopulation composition of T-lymphocytes and NK-cells. CLL patients have been found to have quantitative and functional changes in the subpopulations of T-lymphocytes and NK cells, indicating dysregulation of the immune response, and a high risk of developing infections. Monitoring of immunological parameters for ibrutinib therapy make possible to estimate impact of ibrutinib on the adaptive anti-CLL immune response.

18 July 2023 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
ЕЛЕ. Б. Ликольд
Е. Б. Ликольд
BBBella Biderman
Bella Biderman
IFI. S. Fevraleva
I. S. Fevraleva
NSN. A. Severina
N. A. Severina
EDE. A. Dmitrieva
E. A. Dmitrieva
ASAndrey Sudarikov
Andrey Sudarikov
Introduction. Currently, Ibrutinib is one of the most effective drugs for relapsed and refractory chronic lymphocytic leukemia treatment. In most patients with CLL, ibrutinib causes persistent remissions, but in some patients the disease progresses. Ibrutinib resistance in most cases is associated with the C481S mutation, which corresponds to the c.1441T>A and c.1442G>C substitutions in the BTK gene, however, other variants also exist.Aim — to evaluate variable allele fraction of the BTK gene mutations in patients with relapsed chronic lymphocytic leukemia using the in-house allele-specific real-time PCR test.Materials and methods. The study included material from 102 cases: 39 CLL patients with disease progression on ibrutinib therapy, 24 CLL patients with disease progression on the FCR/FCR-lite protocols, and 38 CLL treatment-naive patients. The control group included 118 patients with non-neoplastic hematological diseases.Results. Using in-house using AS-PCR, we detected the c.1442G>C mutation in 20 out of 39 CLL patients with progression on ibrutinib therapy. Mutation c.1442G>T was detected in 2 patients. In a single patient, two mutations were detected simultaneously: c.1441T>A and c.1442G>C. Another single patient had a combination of three mutations: c.1442G>C, c.1442G>T and c.1442G>A. In 15 patients with progression on ibrutinib therapy, mutations in the BTK gene were not detected. In treatment-naive CLL patients, in the group treated with FCR/FCR-lite regimens, and in the control group of patients with nonneoplastic diseases, mutations in the BTK gene were not detected.Conclusion. Variable allele fraction of exon 15 BTK gene mutations in the patients with CLL progression was successfully determined using in-house AS-PCR test: 50 % of patients had one mutation, 5 % had two mutations, and 2.5 % had three mutations in the BTK gene. Timely detection of these mutations before clinical recurrence may facilitate effective treatment strategy. Since clinical manifestations of ibrutinib resistance appear after an average of 1–2 years, we suggest monitoring BTK mutation load every 3 months in patients with CLL before relapse during treatment with ibrutinib.

14 April 2023 in Hematological Oncology
Verified
Journal Article
Closed access
Maria KislovaMaria Kislova
Maria Kislova
APAndrei Petrenko
Andrei Petrenko
EDElena A. Dmitrieva
Elena A. Dmitrieva
AMAlexander Milenkin
Alexander Milenkin
KNKonstantin E. Nikitin
Konstantin E. Nikitin
ENEugene A. Nikitin
Eugene A. Nikitin

26 December 2022 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
PDF file
EME E Markova
E E Markova
ENEugene Nikitin
Eugene Nikitin
EDE A Dmitrieva
E A Dmitrieva
SMS Yu. Mayorоva
S Yu. Mayorоva
YKYu. B Kochkareva
Yu. B Kochkareva
VPV V Ptushkin
V V Ptushkin
Introduction. Optimal therapy for elderly patients with chronic lymphocytic leukemia (CLL) is the subject of intensive research.Aim – to study the safety of obinutuzumab, as well as the selection of the optimal scheme of its use in patients with CLL, complicated by diabetes mellitus, renal insuffi ciency, cardiac comorbidity.Materials and methods. The study included primary patients with CLL having indications requiring therapy. The inclusion criteria were: Cumulative Illness Rating Scale, CIRS) (CIRS) > 6 and or glomerular fi ltration rate (GFR) < 70 mL/min, the lower limit of GFR was not restricted. The study focused on patients with diabetes mellitus, renal failure and signifi cant cardiac pathology. Patients with Richter’s syndrome, CNS involvement, HBs-antigen, and 17p deletion were not included. In the fi rst cycle obinutuzumab was administered at a dose of 100 or 25 mg on the fi rst day and 900 or 975 mg on the second day, then at a dose of 1000 mg on days 8 and 15. For all subsequent cycles, obinutuzumab was given at a dose of 1000 mg on day 1. The dosage of chlorambucil was 10 mg/m2 from days 1 to 7. Treatment cycles in totals of 6 were repeated every 28 days.Results. The study included 90 patients. Median age was 73.5 years, range – 60–89 years, there were 49 men (54 %) and 41 women (46 %). Twenty-four patients (27 %) had stage C, IGHV unmutated status was detected in 76 % of patients. The median creatinine clearance was 48.6 mL/min (25–110). The median CIRS score was 3 (range – 1–14). Thirty-one patients (34 %) had signifi cant cardiovascular comorbidity (previous myocardial infarction, coronary artery stenting or bypass, HF ≥ II NYHA, peripheral artery disease) as well as hemodynamically signifi cant valvular disease. Fifteen patients (17 %) had diabetes mellitus and 71 patients (79 %) had creatinine clearance < 70 ml/min. Infusion reactions to obinutuzumab grade ≥ II were reported in 29 patients (32 %). Hospitalization on the day of administration or the next day after the fi rst administration was required in 5 cases (5.5 %). Twenty-seven (30 %) patients could not complete 6 cycles. The largest number of patients (14 people, 15.5 %) stopped treatment after 1 course. The causes were the development of persistent cytopenia (n = 4), grade IV reaction to obinutuzumab (n = 3), patient’s refusal (n = 2), infectious complications (n = 2), severe tumor lysis syndrome (n = 1), acute pancreatitis (n = 1) and toxicodermia (n = 1). The leading cause of premature discontinuation on subsequent cycles was persistent neutropenia. Progression during treatment occurred in 3 patients only. Overall survival was signifi cantly predicted by CIRS (maximum discriminatory value of 3, p = 0.013) as well as GFR < 50 mL/min (p = 0.03). No other associations were identifi ed. At least 1 episode of grade III–IV neutropenia occurred in 41 % of patients. Grade IV neutropenia was associated with creatinine clearance < 60 mL/min (p = 0.05), baseline neutrophil level < 2 × 109/L (p = 0.0001), baseline monocyte level < 0.3 × 109/L (p = 0.007) and age > 70 years (p = 0.01). The effectiveness of treatment was evaluated in patients who completed at least 3 cycles of therapy. Complete remission was achieved in 26 patients (35 %), partial remission – in 41 (54 %), stabilization – in 4 (5 %), progression was noted in 3 (4 %). Sixteen patients (18 %) were not available to respond to the assessment. Minimal residual disease < 0.01 % in the bone marrow after completion of treatment was found in 17 patients (19 %), within 0.01–0.9 % – in 25 (28 %) patients. The median follow-up from the date of therapy initiation was 39.7 months (range – 0.6–72 months). The median relapse-free survival was not reached, and 2- and 3-year survival rates were 81 and 62 %, respectively. Poor relapse-free survival signifi cantly correlated with unmutated IGHV genes (HR = 2.4, 95 % CI: 1.12–5.0, p = 0.02) and partial response as opposed to complete response (HR = 3.35; 95 % CI: 1.45–7.7, p = 0.03).Conclusion. The results of our study have practical implications as obinutuzumab is actively integrated into modern treatment regimens. Infusion reactions pose a high risk of complications in elderly patients. The dose of obinutuzumab on day 1 of administration in elderly patients, should not exceed 25 mg. The G-Clb regimen may not be optimal in patients over 75 years of age due to the unpredictable risk of complications. In patients at high risk of neutropenia, it may be appropriate to consider primary prophylaxis. ClbG is an effective regimen that resulted in high rate of MRD-negative responses and prolonged relapse-free survival.